Henry James International Management Inc. Purchases Shares of 43,000 MorphoSys AG (NASDAQ:MOR)

Henry James International Management Inc. bought a new position in MorphoSys AG (NASDAQ:MOR) during the 4th quarter, Holdings Channel.com reports. The institutional investor bought 43,000 shares of the company’s stock, valued at approximately $426,000.

Separately, Exchange Traded Concepts LLC grew its stake in MorphoSys by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 17,437 shares of the company’s stock valued at $173,000 after purchasing an additional 4,421 shares in the last quarter. Institutional investors own 18.38% of the company’s stock.

MorphoSys Price Performance

Shares of MorphoSys stock traded up $0.02 during midday trading on Friday, hitting $17.89. 458,755 shares of the company were exchanged, compared to its average volume of 619,250. The firm has a 50 day simple moving average of $17.95 and a 200-day simple moving average of $12.59. The company has a debt-to-equity ratio of 4.98, a current ratio of 1.38 and a quick ratio of 2.84. MorphoSys AG has a 52 week low of $4.18 and a 52 week high of $18.31. The firm has a market cap of $2.69 billion, a P/E ratio of -5.14 and a beta of 1.15.

MorphoSys (NASDAQ:MOR) last announced its earnings results on Wednesday, March 13th. The company reported $0.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $1.25. MorphoSys had a negative net margin of 226.79% and a negative return on equity of 10,108.30%. The company had revenue of $63.53 million for the quarter, compared to analyst estimates of $76.30 million. Research analysts forecast that MorphoSys AG will post -2.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on MOR shares. Wells Fargo & Company reiterated an “equal weight” rating and set a $18.25 target price (up previously from $17.00) on shares of MorphoSys in a research note on Thursday, March 14th. Morgan Stanley reiterated an “equal weight” rating on shares of MorphoSys in a research report on Friday, January 19th. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $11.78.

About MorphoSys

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.